Trial · NCT01668784
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) at Primary Endpoint | Randomization until 398 deaths, up to May 2015 (approximately 30 months) | All randomized participants; any participants that was randomized to any treatment group in the study. | months | MEDIAN |
| SECONDARY | Investigator-assessed Objective Response Rate (ORR) | from randomization up to disease progression or death (approximately up to 105 Months) | All randomized participants; any participants that was randomized to any treatment group in the study. | percentage of participants | NUMBER |
| SECONDARY | Investigator-assessed Duration of Objective Response | From randomization to date of disease progression or death or censoring if no progression or death occurred (approximately 105 months) | All randomized participants with a response; any participants that were randomized to any treatment group in the study and that had a response. | months | MEDIAN |
| SECONDARY | Investigator-assessed Time to Objective Response | Randomization to date of first response (approximately 105 months) | All randomized participants with a response; any participants that was randomized to any treatment group in the study and that had a response. | months | MEDIAN |
| SECONDARY | Investigator-assessed Time of Progression-free Survival (PFS) | from randomization up to disease progression or death (approximately up to 105 Months) | All randomized participants; any participants that was randomized to any treatment group in the study. | months | MEDIAN |
| SECONDARY | Overall Survival (OS) by Programmed Death-Ligand 1 (PD-L1) Expression Level | Randomization to date of death or date of last contact for patients without documentation of death, up to May 2015 (approximately 30 months) | PD-L1 quantifiable participants; All randomized participants with quantifiable PD-L1 expression at baseline | months | MEDIAN |
| SECONDARY | Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events | Day of first dose to 30 days post study completion (approximately 106 months) | All treated participants; all participants who received at least one dose of nivolumab or everolimus | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Disease-related Symptom Progression (DRSP) | from randomization up to disease progression or death (approximately up to 105 Months) | All randomized participants; any participants that was randomized to any treatment group in the study. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants Meeting Marked Laboratory Abnormality Criteria in Specific Liver and Thyroid Tests | Day 1 to 30 days post study completion (approximately 106 months) | To all treated participants with evaluable measurements | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Hematology and Serum Chemistry Laboratory Parameters by Worse CTC Grade - SI Units | Day 1 to 30 days post study completion (approximately 106 months) | To all treated participants with evaluable measurements | Participants | COUNT_OF_PARTICIPANTS |
| POST_HOC | Extended Collection to Post Hoc Overall Survival (OS) | from randomization up to disease progression or death (approximately up to 105 months) | All Randomized Participants | Months | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01668784/outcomes